Breaking News

Janssen Acquires Corimmun

Gains heart failure drug

Author Image

By: Tim Wright

Editor-in-Chief, Contract Pharma

Janssen-Cilag GmbH has completed the acquisition of CorImmun GmbH, a privately held drug development company, for an undisclosed upfront payment and future milestones.   CorImmun’s lead compound, COR-1, is a small cyclic peptide in early clinical development for the treatment of heart failure. COR-1 has been shown in preclinical studies to improve heart function by decreasing autoimmune, beta 1 receptor-simulating antibody effects. Janssen and its affiliates assume full development and glo...

Continue reading this story and get 24/7 access to Contract Pharma for FREE


Already a subscriber? Sign in

Keep Up With Our Content. Subscribe To Contract Pharma Newsletters